Study: Merck&#39;s Arcoxia Appears Safe Medium Term
291930
Drug firm Merck &amp; Co. will present data this week showing that an experimental arthritis drug, Arcoxia, a treatment in the same class as its recently withdrawn Vioxx, showed no significant
26961
Merck &amp; Co. said the US Food and Drug Administration has requested additional safety and efficacy information on its Vioxx successor, Arcoxia, before it considers granting US approval for the drug.
286317
As drugmakers scramble to grab Vioxx&#39;s multi-billion-dollar share of the arthritis and pain-relief market, patients might find themselves wondering whether the competing medications are much safer.
766518
A study shows promising results for Novartis's COX-2 inhibitor.
537343
An experimental thrombosis pill from   Bayer AG BAYG.DE, seen by analysts as the German group's most   important pipeline asset, has produced promising results in two   clinical trials, researchers said on Tuesday.
655204
Merck &amp; Co. Inc.(MRK.N: Quote, Profile, Research) , reeling from the recent withdrawal of its Vioxx arthritis drug, on Wednesday reaffirmed its 2004 earnings outlook but said earnings in 2005 will be lower than analysts had expected.
613250
Nearly one year ago, Merck received preliminary results from a study of patient records that apparently indicated Vioxx posed cardiovascular risks.
208543
Vioxx was already a big success as an arthritis pain reliever, but Merck &amp; Co. thought it could be an even bigger seller. The drug seemed to have some cancer-prevention qualities
573622
FRIDAY, Oct. 8 (HealthDayNews) -- A week after drug giant Merck & Co. withdrew its arthritis drug Vioxx from the market, doubts are being raised about the safety of the two other approved medications in this class, Bextra and Celebrex.
704575
NEW YORK -- A new study has linked painkillers Vioxx, Celebrex, and Bextra to increased cardiovascular risk, reinforcing findings of other trials that have already sparked concern over the safety of a popular category of drugs.
704046
NEW YORK - Merck &amp; Co.&#39;s new pain reliever, Arcoxia, was gentler on the stomach than an older pain reliever, the New Jersey-based drug maker said as it released results of a new study Tuesday.
707960
German drugs and chemicals group Merck&#39;s third-quarter operating profit rose by a forecast-beating 42 percent, helped by strong sales of cancer drug Erbitux and liquid crystals for flat screen televisions.
4532
Merck &amp; Co. faces a dual threat from health insurers and patients&#39; lawyers, after a US study suggested its Vioxx arthritis drug carries a greater risk than rival medicines.
695440
Now that Merck has removed its arthritis painkiller Vioxx from the market after tests found it increased the risk of heart attacks and strokes, its rival Pfizer is taking a surprising stance.
138190
Merck &amp; Co.&#39;s Vioxx painkiller&#39;s heart risk was evident in studies four years before the drug was recalled -- and it should have been pulled from the market then, according to a study published in the medical journal Lancet.
566881
A paper published Tuesday suggests that Vioxx posed heart risks that a similar drug, Celebrex, does not.
326837
Last weekâs dramatic withdrawal of the COX-2 inhibitor rofecoxib (Vioxx) is discussed in this weekâs lead editorial in THE LANCET, which comments that more vigilant drug licensing is vital to prevent the endangering of patientsâ health.